Keros Therapeutics, Inc. · NASDAQ:KROS
Keros Therapeutics — Technical Presentation (December 2020)
11 slides from Keros Therapeutics's technical presentation, December 2020
Slide 1: KER-050, a modified ActRIIA ligand trap, alleviates cytopenia arising from multiple etiologies
Abstract # 2582 KER-050, a modified ActRIIA ligand trap, alleviates cytopenia arising from multiple etiologies Marina Feigenson, Remya Nathan, Keith Babbs, Chris M Materna, Claire C Tseng, ffolliott M Fisher, Jasbir Seehra, Jennifer L Lachey Keros Therapeutics, Lexington, MA
Slide 2: Disclosures
Disclosures All authors are employees of and shareholders of Keros Therapeutics, Inc
Slide 3: Introduction
Introduction • Signaling by the transforming growth factor-beta (TGF-β) superfamily ligands regulates several stages of red blood cell (RBC) maturation. Studies have demonstrated that inhibition of ligands that signal through SMAD2/3 induce RBC production and increase circulating RBCs, hemoglobin, a
Slide 4: RKER-050 improved anemia in aged animals
RKER-050 improved anemia in aged animals • Anemia is common in aged populations and is often comorbid with disorders of aging such as frailty, leading to significant declines in quality of life. • To test the efficacy of RKER-050 (a research version of KER-050) in age-related anemia, two-year-old, C
Slide 5: RKER-050 improved anemia in aged animals
RKER-050 improved anemia in aged animals Red Blood Cells Hemoglobin Hematocrit 15 20 60 ✱✱✱✱ ✱✱ ✱✱✱✱ RBC (106/µL) HGB (g/dL) HCT(%) 10 15 40 N=8-9 Data is shown as mean ± SEM. Statistical analysis was done by one-way 5 10 20 ANOVA with a Dunnett’s post test. **p<0.01 ***p<0.001 ****p<0.0001 le le le
Slide 6: RKER-050 improved anemia in aged animals
RKER-050 improved anemia in aged animals Red Blood Cells Hemoglobin Hematocrit ✱✱ 15 ✱✱ 20 ✱✱✱ 60 ✱✱✱✱ ✱✱ ✱✱✱✱ RBC (106/µL) HGB (g/dL) HCT(%) 10 15 40 N=8-9 Data is shown as mean ± SEM. 5 10 20 Statistical analysis was done by one-way le le le le 50 le le 50 ANOVA with a Dunnett’s post test. 50 c c
Slide 7: RKER-050 dramatically improved anemia in a mouse model of myelodysplastic syndrome
RKER-050 dramatically improved anemia in a mouse model of myelodysplastic syndrome • Gene fusion of NUP98 and HOXD13, a common mutation resulting in myelodysplastic syndrome (MDS) in humans, was used to model ineffective hematopoiesis due to MDS in mice (MDS mice). • Six-month-old MDS mice were conf
Slide 8: RKER-050 dramatically improved anemia in a mouse model of myelodysplastic syndrome
RKER-050 dramatically improved anemia in a mouse model of myelodysplastic syndrome Red Blood Cells Hemoglobin Hematocrit 11 11 18 50 10 10 /µL) (1066/µL) 16 45 HGB (g/dL) 99 ** HCT(%) * RBC (10 14 40 88 ** * RBC * 77 12 * 35 66 10 30 00 10 20 30 30 40 40 0 10 20 30 40 0 10 20 30 40 Study Day Study D
Slide 9: RKER-050 robustly enhanced recovery from acute blood loss induced anemia
RKER-050 robustly enhanced recovery from acute blood loss induced anemia • Blood loss anemia can occur in multiple clinical settings, including surgery, gastro-intestinal bleeding and physical trauma. • To test the efficacy of RKER-050 in increasing RBCs in response to a model of acute blood loss an
Slide 10: RKER-050 increased platelets after phlebotomy in rats
RKER-050 increased platelets after phlebotomy in rats • In our Phase 1 clinical study meaningful increases in platelets in healthy participants were observed in addition to robust increases in RBCs. In this study, we evaluated the effect of RKER-050 on platelets in a rat phlebotomy model. • In this
Slide 11: Summary and Conclusions
Summary and Conclusions • KER-050 is a modified ActRIIA ligand trap designed to promote hematopoiesis. • RKER-050 showed efficacy in animal models of: • Age-related anemia • Ineffective hematopoiesis in model of myelodysplastic syndrome • Anemia due to acute blood loss • RKER-050 treatment also show
Keros Therapeutics — Technical Presentation (December 2020) on 6ix